Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 5, 2011, Pages 1117-1124

  Radzikowski, Andrzej ^a   Banaszkiewicz, Aleksandra ^a   Łazowska Przeorek, Izabella ^a   Grzybowska Chlebowczyk, Urszula ^b   Woś, Halina ^b   Pytrus, Tomasz ^c   Iwańczak, Barbara ^c   Kowalska Duplaga, Kinga ^d   Fyderek, Krzysztof ^d   Gawrońska, Agnieszka ^a   Karolewska Bochenek, Katarzyna ^a   Kotowska, Maria ^a   Albrecht, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Crohn's Disease; hepatitis A virus; inflammatory bowel disease; pediatric patients

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; AGE FACTORS; CHILD; CROHN DISEASE; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 79953838907     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21465     Document Type: Article

References (36)

1. CDC Morbidity and Mortality Weekly Report. Prevention of hepatitis A through active and passive immunization. Recommendation of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 1996; 45 (RR-15): 1-30.
2. Centers for Disease Control and Prevention. Recommended immunization schedules for person aged 0 through 18 years - United States, 009. MMWR. 2008; 57: 51-52.
3. AAP Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics. 2007; 1: 189-199.
4. Available at: http://www.pzh.gov.pl/oldpage/epimeld/index-p.html#05
5. Hadler SC,. Global impact of hepatitis A virus infection changing patterns. In:, Hollinger FB, Lemon SM, Margolis H,. Viral hepatitis and liver disease. Philadelphia: Williams & Wilkins. 1991; 14-20.
6. Janaszek-Seydlitz W, Bucholc B, Slusarczyk J, et al. The epidemiology of hepatitis A in Poland: prevalence of hepatitis A antibodies in population. 16th European Congress of Clinical Microbiology and Infectious Diseases Nice, France, April 1-4 2006. Abstract p 783.
7. Winesett M,. Inflammatory bowel disease in children and adolescents. Pediatr Ann. 1997; 26: 227-234. (Pubitemid 28075546)
8. Weersma RK, van Dullemen HM, van der Steege G, et al. Review article: inflammatory bowel disease and genetics. Aliment Pharmacol Ther. 2007; 26 (suppl 2): 57-65. (Pubitemid 350233321)
9. Aberra FN, Lichtenstein GR,. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 685-695. (Pubitemid 40961083)
10. Rothfuss KS, Stange EF, Herrlinger KR,. Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol. 2006; 12: 4819-4831. (Pubitemid 44323206)
11. Navaneethan U, Shen B,. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010 [Epub ahead of print].
12. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338: 286-290. (Pubitemid 28065254)
13. Keeffe EB,. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995; 90: 201-205.
14. Stevens R, Oliver M, Brogan M, et al. Defective generation of tetanus-specific antibody producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology. 1985; 88: 1860-1866. (Pubitemid 15052298)
15. Melmed GY, Agarwal N, Frenck RW, et al. Immunosupression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2009; 105: 148-154.
16. Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr. 2007; 44: 431-435. (Pubitemid 46573225)
17. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunization in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 677-692. (Pubitemid 39276481)
18. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Gastroenterology. 2009; 3: 47-91.
19. Mamula P, Markowitz JE, Piccolo DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 851-856. (Pubitemid 47031059)
20. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 444-453.
21. Rybicka K, Romanowska M, Banaszkiewicz A, et al. Immunological response after vaccination against influenza A and B in children with inflammatory bowel disease. (abstract) ESPID Porto 2007.
22. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 1-7.
23. Just M, Berger R,. Reactogenicity and immunogenicity of inactivated hepatitis A vaccine. Vaccine. 1992; 10 (suppl 1): S110-S113.
24. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994; 271: 1328-1334. (Pubitemid 24132458)
25. Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003; 37: 258-261. (Pubitemid 39274514)
26. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999; 94: 1601-1604. (Pubitemid 29260452)
27. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001; 36: 265-269. (Pubitemid 32234575)
28. Dotan I, Vigodman S, Malter L, et al. Azathioprine/6-mercaptopurine therapy has no significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology. 2007; 132: A-51.
29. Elkayam O, Ablin J, Caspi D,. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Ann Rheum Dis. 2006; 65: 191-194.
30. Nies K, Boyer R, Stevens R, et al. Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 1980; 23: 1343-1350. (Pubitemid 11199873)
31. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 1001; 29: 2555-2557.
32. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994; 21: 1203-1206. (Pubitemid 24234652)
33. Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer. 2004; 101: 635-641. (Pubitemid 38970616)
34. Confavreux C, Suissa S, Saddier P, et al. Vaccination and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001; 344: 319-326. (Pubitemid 32107639)
35. McMahon BJ, Beller M, Willimas J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996; 150: 733-739. (Pubitemid 26230875)
36. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994; 44: 446-451.